The Battle for Multiple Myeloma: Bristol Myers Squibb vs. Janssen
This ongoing competition between Janssen oncology drugs and BMS multiple myeloma drugs will continue to accelerate innovation, improve patient access, and influence payer strategies throughout the global multiple myeloma treatment market
